Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 3/20 | 0.86 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764010 | 1.00 | BDKRB1 (0.86) | BDKRB1F10AVPR1AF2SIGMAR1 | |
| SCHEMBL6763320 | 0.98 | BDKRB1 (0.83) | BDKRB1F10AVPR1AF2OPRM1 | |
| SCHEMBL6763203 | 0.98 | BDKRB1 (0.83) | BDKRB1F10AVPR1AF2OPRM1 | |
| SCHEMBL6762372 | 0.96 | BDKRB1 (0.78) | BDKRB1F10AVPR1AF2OPRM1 | |
| SCHEMBL6762376 | 0.96 | BDKRB1 (0.78) | BDKRB1F10AVPR1AF2OPRM1 | |
| SCHEMBL6766417 | 0.93 | BDKRB1 (0.82) | BDKRB1AVPR1ASIGMAR1BCHEACHE | |
| SCHEMBL6766411 | 0.93 | BDKRB1 (0.82) | BDKRB1AVPR1ASIGMAR1BCHEACHE | |
| SCHEMBL6761801 | 0.92 | BDKRB1 (1.00) | BDKRB1F10AVPR1AF2SIGMAR1 | |
| SCHEMBL6763240 | 0.91 | BDKRB1 (0.79) | BDKRB1AVPR1A | |
| SCHEMBL6763237 | 0.91 | BDKRB1 (0.79) | BDKRB1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885F10 4430/4885AVPR1A 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.